|
| 產(chǎn)地 | 進口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS11218 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-RNF56/CBLB |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human RNF56/CBLB |
產(chǎn)品訂購信息：
英文名稱 Anti-RNF56/CBLB
中文名稱 環(huán)指蛋白56規(guī)格
別 名 Cas Br M (murine) ecotropic retroviral transforming sequence b; Casitas B lineage lymphoma b; Casitas B lineage lymphoma proto oncogene b; Cbl b; E3 ubiquitin protein ligase CBL B; RING finger protein 56; RNF56; SH3 binding protein CBL B; Signal transduction protein CBL B.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 信號轉(zhuǎn)導(dǎo)
蛋白分子量 predicted molecular weight: 108kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human RNF56/CBLB
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
環(huán)指蛋白56規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 CBLB (Cas Br M (murine) ecotropic retroviral transforming sequence b) has high homology to CBL, the proto-oncogene that induces pre-B cell lymphomas and myeloid leukemias in mice. Like CBL, CBLB contains putative nuclear localization signal, zinc finger, leucine zipper, and proline-rich domains. CBLB associates with FYN, FGR, and PLCG1. Acts an E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. May also be involved in EGFR ubiquitination and internalization. In addition to its role in the prevention of chronic inflammation and autoimmunity, CBLB also has a function in acute lung inflammation. There are 4 isoforms produced by alternative splicing.
Function : E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production. Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation. In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy. In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation. May also be involved in EGFR ubiquitination and internalization. [PATHWAY] Protein modification; protein ubiquitination.
Subunit : Interacts with SH3 domain-containing proteins LCK, CRK and SORBS1. Interacts with LCP2 and ZAP70. May interact with CBL. Interacts with SH3 domain-containing proteins VAV1, FYN, FGR, PLCG1, GRB2, CRKL, PIK3R1 and SH3KBP1/CIN85. Identified in heterotrimeric complexes with SH3KBP1/CIN85, CD2AP and ARHGEF7, where one CBLB peptide binds two copies of the other protein. Interacts with poly-ubiquitinated proteins. Dimerization is required for the binding of poly-ubiquitin, but not for the binding of mono-ubiquitin.
Subcellular Location : Cytoplasmic and Nuclear
Tissue Specificity : Expressed in placenta, heart, lung, kidney, spleen, ovary and testis, as well as fetal brain and liver and hematopoietic cell lines, but not in adult brain, liver, pancreas, salivary gland, or skeletal muscle. Present in lymphocytes (at protein level).
Post-translational modifications : Phosphorylated on tyrosine and serine residues upon TCR or BCR activation, and upon various types of cell stimulation.
Auto-ubiquitinated upon EGF-mediated cell activation or upon T-cell costimulation by CD28; which promotes proteasomal degradation.
Similarity : Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain.
Notch1/MOTC(Neurogenic locus notch homolog protein 1) 跨膜受體蛋白Notch-1抗原Multi-class antibodies規(guī)格： 0.5mg
Anti-AQP3 水通道蛋白-3抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh phospho-ATG4D(Ser467) 磷酸化自噬相關(guān)蛋白4D抗體 規(guī)格 0.1ml
山羊抗人 IgG(H+L)/HRP 0.1ml 美國Jackson公司分裝
VGLL1 英文名稱： 轉(zhuǎn)錄輔助因子退變樣蛋白1抗體 0.2ml
DENND2C 英文名稱： MAP激酶激活死亡域蛋白2C抗體 0.2ml
Anti-AQP3 水通道蛋白-3抗體Multi-class antibodies規(guī)格： 0.1ml
Anti-P-HP1/FITC 熒光素標(biāo)記抗異染色質(zhì)蛋白1磷酸化抗體(果蠅)IgGMulti-class antibodies規(guī)格： 0.2ml
Rabbit Anti-human IgG 兔抗人IgG (親和層析純化)Multi-class antibodies規(guī)格： 1mg
病毒糖蛋白抗體 Anti-Glycoprotein [Rubella virus] 0.2ml
Rabbit Anti-Biotin/HRP 辣根過氧化物酶標(biāo)記的兔抗生物素抗體IgG 0.1ml
FAHD2A 英文名稱： 延胡索酰乙酰乙酸水解酶抗體 0.2ml
Rhesus antibody Rh phospho-SHC (Tyr317) 磷酸化SH2結(jié)構(gòu)域轉(zhuǎn)化蛋白1抗體 規(guī)格 0.1ml
Rabbit Anti-human IgG 兔抗人IgG (親和層析純化)Multi-class antibodies規(guī)格： 1mg
S100A4 英文名稱： S100A4抗體 0.1ml
ETV3L 英文名稱： ETV3L蛋白抗體 0.2ml
鼠抗F1蛋白/耶爾森氏菌莢膜抗原F1單克隆抗體 Mouse Anti-YERSINIA PESTIS Monoclonal Antibody 0.1ml
Anti-TSH/Biotin 生物素化促甲狀腺素抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh phospho-IKK beta(Ser471) 磷酸化KB抑制蛋白激酶β抗體 規(guī)格 0.1ml
TrK A (h-NGFR) (p140- TrK A) 神經(jīng)生長因子的一種(抗原)Multi-class antibodies規(guī)格： 0.5mg
293T, SV40轉(zhuǎn)化的人胚腎上皮細(xì)胞系
DCE 雞胚成纖維細(xì)胞
IL24 Others Human 人 IL-24 / Ierleukin-24 人細(xì)胞裂解液 (陽性對照)
CM-M093小鼠胎兒真皮成纖維細(xì)胞完全培養(yǎng)基100mL
髓核細(xì)胞培養(yǎng)基NPCM-prf
EB病毒轉(zhuǎn)化的人B淋巴細(xì)胞;KMY0901 人真皮淋巴上皮細(xì)胞完全培養(yǎng)基 100mL
CL-0072Daudi(人細(xì)胞)5×106cells/瓶×2
SDF2 Others Human 人 SDF2 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對照)
細(xì)胞凋亡蛋白酶-3分析試劑盒CAS
HT-29細(xì)胞，人細(xì)胞 人胚腎細(xì)胞,293細(xì)胞 腎系膜細(xì)胞Many types of cells包裝：5 ×105次方(1ml)
家兔骨髓間充質(zhì)干細(xì)胞;2012083MSC
SFRP4 Others Human 人 sFRP4 人細(xì)胞裂解液 (陽性對照)
環(huán)指蛋白56規(guī)格 293T, SV40轉(zhuǎn)化的人胚腎上皮細(xì)胞系
DCE 雞胚成纖維細(xì)胞
IL24 Others Human 人 IL-24 / Ierleukin-24 人細(xì)胞裂解液 (陽性對照)
CM-M093小鼠胎兒真皮成纖維細(xì)胞完全培養(yǎng)基100mL
髓核細(xì)胞培養(yǎng)基NPCM-prf
EB病毒轉(zhuǎn)化的人B淋巴細(xì)胞;KMY0901 人真皮淋巴上皮細(xì)胞完全培養(yǎng)基 100mL
抗體的生物素化標(biāo)記實驗要點：
1. 環(huán)指蛋白56規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）環(huán)指蛋白56規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
|
|
|
|
|
